Skip to main content
SpringerLink
Log in

Liposomal bupivacaine reduces hospital costs of TKA

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2014 US dollars

Reference

  • Kirkness CS, et al. Cost-benefit evaluation of liposomal bupivacaine in the management of patients undergoing total knee arthroplasty. American Journal of Health-System Pharmacy 73: e247-54, No. 9, May 2016. Available from: URL: http://doi.org/10.2146/ajhp150332

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liposomal bupivacaine reduces hospital costs of TKA. PharmacoEcon Outcomes News 752, 25 (2016). https://doi.org/10.1007/s40274-016-3019-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-3019-z

Search

Navigation